3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Terminated
3
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
3
Conditions
Breast Neoplasms
5
Neoplasm Metastasis
3
Triple Negative Breast Neoplasms
1
Interventions
Paclitaxel
50
Capecitabine
50
Trastuzumab
38
Fulvestrant
31
pembrolizumab
27
Cyclophosphamide
27
Carboplatin
27
Gemcitabine
23
Letrozole
21
palbociclib
19
Docetaxel
19
Lapatinib
18
Bevacizumab
18
exemestane
17
eribulin
15
Everolimus
14
abemaciclib
13
Vinorelbine
13
Nivolumab
13
Magnetic Resonance Spectroscopy
12
Cisplatin
12
Anastrozole
12
trastuzumab deruxtecan
11
Zoledronic Acid
11
Doxorubicin
11
Albumin-Bound Paclitaxel
11
olaparib
10
Tamoxifen
10
Specimen Handling
10
Radiotherapy
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
tesetaxel
×
Breast
×
Clear all
NCT03326674
2021-07-30
CONTESSA
Odonate Therapeutics, Inc.
Phase 3
Terminated
685 enrolled
NCT03858972
2021-07-30
CONTESSA 2
Odonate Therapeutics, Inc.
Phase 2
Terminated
152 enrolled
NCT03952325
2021-07-30
CONTESSA TRIO
Odonate Therapeutics, Inc.
Phase 2
Terminated
294 enrolled